{"product_id":"retatrutide-10mg-1","title":"RETATRUTIDE 10MG","description":"\u003cp\u003e\u003cmeta charset=\"utf-8\"\u003e\u003cspan\u003eRetatrutide is one of the most promising new weight-loss and metabolic health drugs currently in clinical development. Unlike existing GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) or dual agonists like tirzepatide (Mounjaro, Zepbound), Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. This unique mechanism has shown unprecedented results in early clinical trials, with participants losing over 24% of their body weight in less than a year at the highest studied doses.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e60 CLICKS = 2MG \u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRetatrutide (also known as LY-3437943) is an experimental medication developed by Eli Lilly that is being studied as a next-generation treatment for obesity, overweight, and related metabolic conditions such as type 2 diabetes. It represents a new class of therapies called “triple agonists,” meaning it simultaneously activates three key hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This combined activity helps regulate appetite, improve insulin sensitivity, slow gastric emptying to promote fullness, and enhance fat burning.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eKey Points:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRetatrutide is given as a once-weekly subcutaneous injection.\u003c\/li\u003e\n\u003cli\u003eStepwise escalation is critical to reduce gastrointestinal intolerance.\u003c\/li\u003e\n\u003cli\u003eMost participants in trials reached 8–12 mg weekly, which delivered the strongest results.\u003c\/li\u003e\n\u003cli\u003eDosing protocols may be refined in Phase 3 and post-approval, but gradual titration will remain the standard.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eDosing Protocol : \u003c\/strong\u003e\u003cbr\u003eSuggested weekly titration approach from clinical trials.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eStart : 2mg weekly for 4 weeks to assess tolerance.\u003c\/li\u003e\n\u003cli\u003eEscalate : Increase by 2-4 mg every 4 weeks as tolerated.\u003c\/li\u003e\n\u003cli\u003eTarget : 6-8 mg weekly (standard), 12mg weekly (advanced\/aggressive).\u003c\/li\u003e\n\u003cli\u003eFrequency : Once per week (subcutaneous), same day each week.\u003c\/li\u003e\n\u003cli\u003eCycle Length : Minimum 24 weeks; trials extended to 48 weeks.\u003c\/li\u003e\n\u003cli\u003eTiming : Any consistent day\/time; rotate injection sites with each dose.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWeeks 1-4 : 2mg = 60 clicks\u003cbr\u003eWeeks 5-8 : 4mg = 120 clicks\u003cbr\u003eWeeks 9-12 : 8mg = 240 clicks\u003cbr\u003eWeeks 13+ : 12mg = 360 clicks\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCommon Side Effects :\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAcross Phase 2 trials, participants experienced dose-dependent GI symptoms that are characteristic of GLP-1 receptor agonists:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNausea — most frequent, especially during dose escalation\u003c\/li\u003e\n\u003cli\u003eVomiting — typically mild to moderate, subsiding with continued use\u003c\/li\u003e\n\u003cli\u003eDiarrhea and constipation — fluctuating depending on individual tolerance\u003c\/li\u003e\n\u003cli\u003eAbdominal discomfort — transient and often improved over time\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"nexus pharmaceuticals","offers":[{"title":"Default Title","offer_id":48845384483070,"sku":null,"price":6000.0,"currency_code":"THB","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0828\/0604\/6974\/files\/reta20penbox-Photoroom_1.jpg?v=1788277363","url":"https:\/\/pepthai.com\/products\/retatrutide-10mg-1","provider":"PEPTHAI","version":"1.0","type":"link"}